Quirino T, Bonfanti P, Arcidiacono M, Pusterla L, Cagni A, Scaglione F, Milazzo F
Biomed Pharmacother. 1999 Jun;53(5-6):286-7. doi: 10.1016/s0753-3322(99)80101-2.
This trial was conducted to study the frequency of the slow acetylator phenotype in asymptomatic HIV patients having no previous reaction to sulfa-drugs, and to compare this frequency with the frequency found in healthy controls. Results show that HIV alone is not capable of modifying the acetylator phenotype; the prevalence of slow acetylator phenotype is the same in immune competent subjects and HIV-positive patients. It is more common in HIV-positive patients with a CD4+ lymphocyte count of less than 200 mm-3.
本试验旨在研究既往对磺胺类药物无反应的无症状HIV患者中慢乙酰化酶表型的频率，并将该频率与健康对照者中的频率进行比较。结果表明，仅HIV本身并不能改变乙酰化酶表型；免疫功能正常的受试者和HIV阳性患者中慢乙酰化酶表型的患病率相同。在CD4+淋巴细胞计数低于200/mm³的HIV阳性患者中更为常见。
